Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear path toward resolving the disparity
A Covid treatment center in Rajasthan, India, in May, 2021. Merck, the maker of a new antiviral pill, will allow generic manufacturers in India to produce the pills at a far lower price in more than 100 poorer countries. Photo by Rebecca Conway/Getty Images
©2019 New York Times News Service